Harrow Health, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. on January 27, 2021. The filing discloses material information regarding a clinical trial milestone achieved by Surface Ophthalmics, Inc. ("Surface"), a company in which Harrow holds a significant equity stake.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for Harrow Health, Inc. for the reporting period. The document focuses on a strategic investment update rather than consolidated financial performance.
Material Changes and Investment Details
- Surface Ophthalmics Milestone: On January 27, 2021, Surface announced the first patient dosing in a head-to-head Phase II trial for its drug candidate SURF-100 (mycophenolate sodium and betamethasone in Klarity vehicle) for chronic dry eye disease.
- Trial Comparison: The study compares SURF-100 against leading competitors Xiidra (lifitegrast) and Restasis (cyclosporine).
- Harrow's Stake: Harrow Health currently owns 3,500,000 shares of Surface common stock, representing approximately 30% of Surface's issued and outstanding voting interests.
- Additional Rights: Harrow holds a mid-single digit royalty right on net sales of SURF-100.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on Harrow's overall outlook, or specific risk factors beyond the inherent uncertainties of clinical trials. The document serves as a disclosure of the Surface press release, which is incorporated by reference as Exhibit 99.1.
Key Facts for Investor Verification
- Verify the full text of the Surface Ophthalmics press release (Exhibit 99.1) for detailed trial design and endpoints.
- Confirm the current valuation and liquidity of Harrow's 30% equity stake in Surface Ophthalmics.
- Monitor future filings for updates on the SURF-100 Phase II trial results and potential royalty revenue recognition.
- Review Harrow's most recent 10-K or 10-Q for consolidated financial metrics not included in this 8-K.